Autopsy report · NCT01251809
Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 56 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- medac GmbH
- Sponsor type
- Industry
- Conditions
- Acute Lymphoblastic Leukaemia
- Interventions
- Oncaspar; PEG-rASNase
- Participants
- 56 (planned, not actual)
- Sites
- 30
- Countries
- Germany
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.